阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AZN 阿斯利康

盘前交易 07-07 06:51:44 EDT

190.16

-4.99

-2.56%

盘前190.42

+0.26+0.14%

06:45 EDT

最高190.24	最低186.24	成交量187.20万
今开190.20	昨收195.15	日振幅2.05%
总市值2,949亿	流通市值2,936亿	总股本15.51亿
成交额3.53亿	换手率0.12%	流通股本15.44亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"AZN","market":"US","secType":"STK","nameCN":"阿斯利康","latestPrice":190.16,"timestamp":1783368000000,"preClose":195.15,"halted":0,"volume":1872031,"hourTrading":{"tag":"盘前","latestPrice":190.42,"preClose":190.16,"latestTime":"06:45 EDT","volume":503,"amount":95541.35415,"timestamp":1783421111411,"change":0.26,"changeRate":0.001367,"amplitude":0.006731},"delay":0,"changeRate":-0.025570074301819158,"floatShares":1544000000,"shares":1551000000,"eps":6.639935,"marketStatus":"盘前交易","change":-4.99,"latestTime":"07-07 06:51:44 EDT","open":190.2,"high":190.24,"low":186.235,"amount":353430897.61833,"amplitude":0.020523,"askPrice":190.51,"askSize":100,"bidPrice":190.43,"bidSize":85,"shortable":3,"etf":0,"ttmEps":6.639935,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783431000000},"marketStatusCode":1,"adr":1,"adrRate":0.5,"listingDate":737179200000,"exchange":"NYSE","adjPreClose":190.16,"dividendRate":0.0167,"preHourTrading":{"tag":"盘前","latestPrice":190.42,"preClose":190.16,"latestTime":"06:45 EDT","volume":503,"amount":95541.35415,"timestamp":1783421111411,"change":0.26,"changeRate":0.001367,"amplitude":0.006731},"postHourTrading":{"tag":"盘后","latestPrice":190.16,"preClose":190.16,"latestTime":"19:47 EDT","volume":112603,"amount":21412156.0715,"timestamp":1783381640357,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.7817265916988081,"impliedVol":0.3164,"impliedVolPercentile":0.892},"requestUrl":"/m/hq/s/AZN","defaultTab":"news","newsList":[{"id":"1195870714","title":"异动解读｜阿斯利康盘中下跌3.2%，报187.63美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1195870714","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195870714?lang=zh_cn&edition=full","pubTime":"2026-07-06 21:43","pubTimestamp":1783345400,"startTime":"0","endTime":"0","summary":"7月6日，阿斯利康盘中下跌3.2%，报187.63美元/股，成交额3646.47万美元。阿斯利康所在的制药行业中，个股普遍承压，其中礼来跌1.56%，强生跌1.95%，辉瑞跌2.14%，默沙东跌1.2%，诺和诺德跌3.31%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648321696","title":"石药集团盘初涨近7% 石药集团与阿斯利康达成17.7亿美元新合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2648321696","media":"新浪港股","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648321696?lang=zh_cn&edition=full","pubTime":"2026-07-03 09:41","pubTimestamp":1783042860,"startTime":"0","endTime":"0","summary":"　　石药集团早盘涨近7%，截至发稿，股价上涨4.64%，现报7.90港元，成交额2.37亿港元。　　石药集团宣布，与阿斯利康达成小核酸药物合作。　　根据该协议的条款，石药集团与阿斯利康将针对两个靶点共同发现和开发具备治疗肾脏疾病多种适应症潜力的临床前候选药物。石药集团将保留其中一个 PCC 在中国境内开发、生产和商业化的全部权益。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-07-03/doc-inifntfa5634037.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1951186391.HKD","01093","AZN","LU0432979614.USD","LU0314109678.HKD","BK4588","LU1993786604.SGD","LU0326950275.SGD","LU1807302812.USD","LU0708994859.HKD","IE0008368742.USD","IE00B031HY20.USD","LU0128525929.USD","LU0310800379.SGD","LU0058720904.USD","LU0501845795.SGD","LU1328277881.USD","IE00BZ08YR35.GBP","HK0000165453.HKD","LU1829250122.USD","LU0889565916.HKD","LU2237443978.SGD","LU1226288253.USD","LU2237443465.HKD","IE00B3T34201.USD","IE00B543WZ88.USD","LU1813983027.USD","LU0029864427.USD","LU2089984988.USD","BK1191","LU1152091168.USD","LU0880133367.SGD","LU0072913022.USD","LU2456880835.USD","LU0315179316.USD","AZNH","LU1226288170.HKD","SG9999004220.SGD","BK4568","LU2236285917.USD","LU0109394709.USD","LU0289739699.SGD","BK1521","BK4585","LU2462157665.USD","LU2237443382.USD","IE00BZ08YS42.EUR","LU1152091754.HKD","IE00B5MMRT66.SGD","LU1226287792.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648686711","title":"阿斯利康涨幅扩大，触及盘中高点，最新涨幅为6%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2648686711","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648686711?lang=zh_cn&edition=full","pubTime":"2026-07-02 23:04","pubTimestamp":1783004682,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1267930573.SGD","LU0128525929.USD","IE00B3T34201.USD","AZNH","LU0310800379.SGD","LU2089984988.USD","LU2468319806.SGD","LU0029864427.USD","LU2237443978.SGD","BK4588","LU0109394709.USD","BK4007","LU0889565916.HKD","LU2236285917.USD","BK4568","LU0432979614.USD","LU2462157665.USD","LU0320765992.SGD","LU1829250122.USD","LU2237443549.SGD","LU2237443895.HKD","LU2417539215.USD","LU2237443622.USD","AZN","LU0289739699.SGD","BK4585","LU2456880835.USD","LU0058720904.USD","LU2237443382.USD","LU0708994859.HKD","LU2237443465.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198816064","title":"异动解读｜阿斯利康盘中上涨3.23%，与石药集团达成价值最高17.7亿美元siRNA药物合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1198816064","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198816064?lang=zh_cn&edition=full","pubTime":"2026-07-02 21:42","pubTimestamp":1782999770,"startTime":"0","endTime":"0","summary":"7月2日，阿斯利康盘中上涨3.23%，报189.84美元/股，成交额3577.99万美元。消息面上，阿斯利康与石药集团旗下巨石生物签署合作、选择权及授权协议，双方将利用石药自主研发的siRNA药物发现及肝外递送平台，共同开发靶向肾脏疾病的小干扰核酸创新疗法。根据协议，阿斯利康将支付3000万美元首付款，并享有全球或中国以外地区的独家开发及商业化选择权，潜在里程碑付款合计最高可达17.7亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648688848","title":"多股突发利好公告，石药联手阿斯利康、神州数码中标移动服务器大单","url":"https://stock-news.laohu8.com/highlight/detail?id=2648688848","media":"财闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648688848?lang=zh_cn&edition=full","pubTime":"2026-07-02 20:51","pubTimestamp":1782996660,"startTime":"0","endTime":"0","summary":"合同中标与战略合作方面，石药创新控股子公司将携手阿斯利康，围绕新型小干扰核酸候选药物达成深度战略合作，旗下 SYS6043同步纳入突破性治疗品种名单；东安动力二季度斩获8家企业共计12项定点协议，拓展下游市场；云南能投拿下华宁县大龙山风电场（二期）开发权；神州数码控股子公司成功中标中国移动 PC 服务器集中采购项目。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-07-02/doc-inifmmmu2690850.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00BZ08YT58.USD","LU2237443622.USD","LU2456880835.USD","01093","LU0708994859.HKD","LU1152091168.USD","HK0000165453.HKD","LU2236285917.USD","LU0109394709.USD","IE00B031HY20.USD","LU2468319806.SGD","LU2417539215.USD","BK0250","LU2089984988.USD","IE00BZ08YR35.GBP","LU1960683339.HKD","LU0889565916.HKD","LU0432979614.USD","LU1008478684.HKD","LU1993786604.SGD","AZN","LU0058720904.USD","LU0310800379.SGD","000034","LU2237443978.SGD","LU2039709279.SGD","BK1191","BK4588","LU0067412154.USD","LU0315179316.USD","LU1226288253.USD","LU2237443382.USD","LU1328277881.USD","IE00B5MMRT66.SGD","BK1515","LU2237443549.SGD","LU1807302812.USD","AZNH","IE00B3T34201.USD","LU0320765992.SGD","LU1829250122.USD","SG9999004220.SGD","LU1226288170.HKD","LU0289739699.SGD","LU0029864427.USD","IE00BZ08YS42.EUR","LU0880133367.SGD","LU0072913022.USD","LU2237443895.HKD","LU0326950275.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648506369","title":"阿斯利康与石药合作开发新型小核酸药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2648506369","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648506369?lang=zh_cn&edition=full","pubTime":"2026-07-02 17:49","pubTimestamp":1782985786,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4568","LU0708994859.HKD","LU0432979614.USD","LU2417539215.USD","LU0320765992.SGD","LU1829250122.USD","LU0128525929.USD","LU2456880835.USD","LU2237443978.SGD","LU0058720904.USD","LU2236285917.USD","LU0289739699.SGD","LU0889565916.HKD","BK4007","BK4585","LU2462157665.USD","LU2237443895.HKD","LU2237443622.USD","IE00B3T34201.USD","BK4588","AZN","LU1267930573.SGD","LU2237443465.HKD","AZNH","LU0029864427.USD","LU2468319806.SGD","LU2237443549.SGD","LU0109394709.USD","LU0310800379.SGD","LU2089984988.USD","LU2237443382.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648503310","title":"石药创新(300765.SZ)子公司巨石生物与阿斯利康达成新型肝外递送小干扰核酸创新药物战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2648503310","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648503310?lang=zh_cn&edition=full","pubTime":"2026-07-02 16:53","pubTimestamp":1782982410,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药创新 发布公告，公司的控股子公司石药集团巨石生物制药有限公司与阿斯利康于2026年7月1日签署《合作、选择权及授权协议》，将与阿斯利康在新型小干扰核酸候选药物领域开展战略合作，开发新型肝外递送小干扰分子核酸候选药物。阿斯利康将向巨石生物支付首付款3,000万美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1462313.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1267930573.SGD","LU0320765992.SGD","LU2468319806.SGD","LU0109394709.USD","LU2089984988.USD","BK4568","LU0029864427.USD","300765","159992","AZN","LU0708994859.HKD","LU2237443465.HKD","LU2237443622.USD","BK4007","LU2462157665.USD","BK4588","BK0226","LU2417539215.USD","06978","LU0310800379.SGD","LU2237443978.SGD","BK1161","LU2236285917.USD","LU2237443895.HKD","BK1574","LU0058720904.USD","LU2237443382.USD","LU0128525929.USD","LU1829250122.USD","AZNH","LU2456880835.USD","LU0432979614.USD","LU2237443549.SGD","LU0289739699.SGD","LU0889565916.HKD","BK4585","IE00B3T34201.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648508319","title":"石药集团称与阿斯利康就开发SIRNA药物订立合作、 选择权及授权协议。","url":"https://stock-news.laohu8.com/highlight/detail?id=2648508319","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648508319?lang=zh_cn&edition=full","pubTime":"2026-07-02 16:32","pubTimestamp":1782981130,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["AZNH","LU2468319806.SGD","LU2237443978.SGD","LU0310800379.SGD","LU0320765992.SGD","LU2236285917.USD","LU0128525929.USD","LU2237443382.USD","LU1829250122.USD","BK4007","IE00B3T34201.USD","LU0289739699.SGD","LU2417539215.USD","LU2237443895.HKD","LU2237443549.SGD","BK4568","LU0109394709.USD","LU0029864427.USD","LU2462157665.USD","LU2237443465.HKD","LU2237443622.USD","LU0058720904.USD","LU0432979614.USD","LU0708994859.HKD","LU1267930573.SGD","BK4588","LU0889565916.HKD","BK4585","LU2456880835.USD","AZN","LU2089984988.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648579477","title":"创新药企携手阿斯利康再达重磅国际合作！全市场仅有的恒生创新药ETF华泰柏瑞连续9个交易日成交额突破10亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2648579477","media":"新浪基金","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648579477?lang=zh_cn&edition=full","pubTime":"2026-07-02 13:17","pubTimestamp":1782969420,"startTime":"0","endTime":"0","summary":"某港股龙头药企发布公告，旗下子公司与阿斯利康达成战略合作，双方将携手开展新型靶免联合疗法用于非小细胞肺癌的临床试验，这一合作再度引发市场对国产创新药板块的关注。　　目前市场上仅有的跟踪恒生创新药指数的ETF——恒生创新药ETF华泰柏瑞交投热度居高不下，产品已连续9个交易日单日成交额突破10亿元，本周一更是达27.64亿元，创下今年4月3日之后阶段新高，最新规模24.48亿元，场内流动性表现较亮眼。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-07-02/doc-inifkuqa2716838.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2468319806.SGD","LU2237443549.SGD","LU0320765992.SGD","LU0289739699.SGD","LU2417539215.USD","LU0109394709.USD","BK4588","LU1267930573.SGD","BK4007","LU0432979614.USD","IE00B3T34201.USD","LU0128525929.USD","520500","BK4585","159992","LU0058720904.USD","LU0889565916.HKD","LU2237443382.USD","LU2237443978.SGD","BK4568","LU0310800379.SGD","LU2237443895.HKD","LU0029864427.USD","AZNH","LU2456880835.USD","LU2237443622.USD","LU2089984988.USD","LU2462157665.USD","LU2236285917.USD","LU1829250122.USD","BK1161","BK1574","LU0708994859.HKD","06978","AZN","LU2237443465.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648152730","title":"和誉在港交所公告，公司之附属公司和誉医药宣布，与阿斯利康签署战略合作协议，共同推进一项新型靶免联合疗法治疗非小细胞肺癌的","url":"https://stock-news.laohu8.com/highlight/detail?id=2648152730","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648152730?lang=zh_cn&edition=full","pubTime":"2026-07-02 08:16","pubTimestamp":1782951413,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["AZN","BK4007","LU2237443465.HKD","BK4568","LU2237443382.USD","LU0708994859.HKD","LU0432979614.USD","LU0029864427.USD","LU0889565916.HKD","LU0310800379.SGD","LU0289739699.SGD","LU0109394709.USD","LU2237443978.SGD","LU2468319806.SGD","LU2456880835.USD","LU1829250122.USD","LU2237443895.HKD","LU1267930573.SGD","AZNH","LU0058720904.USD","LU0128525929.USD","LU2089984988.USD","IE00B3T34201.USD","LU2236285917.USD","LU0320765992.SGD","LU2417539215.USD","LU2462157665.USD","BK4588","LU2237443549.SGD","BK4585","LU2237443622.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648220025","title":"和誉-B(02256)附属与阿斯利康达成战略合作开展同类首创口服PD-L1抑制剂ABSK043联合泰瑞沙®治疗非小细胞肺癌的临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2648220025","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648220025?lang=zh_cn&edition=full","pubTime":"2026-07-02 08:06","pubTimestamp":1782950774,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B 发布公告，本公司的附属公司上海和誉生物医药科技有限公司宣布，与阿斯利康签署战略合作协议，共同推进一项新型靶免联合疗法治疗非小细胞肺癌的临床研究。该联合研究是一项多中心、开放的I/II期临床试验，旨在评估和誉医药自主研发的同类首创口服小分子PD-L1抑制剂 ABSK043联合阿斯利康第三代EGFR-TKI泰瑞沙 ，用于治疗EGFR突变合并PD-L1阳性的局部晚期或转移性NSCLC患者中的安全性和疗效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1462072.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AZNH","LU2237443465.HKD","IE00B543WZ88.USD","LU2237443895.HKD","AZN","LU2456880835.USD","BK4588","LU0320765992.SGD","LU0708994859.HKD","LU2237443978.SGD","LU2236285917.USD","LU0128525929.USD","LU1829250122.USD","BK4585","LU2237443382.USD","LU0310800379.SGD","BK4007","BK4023","02256","LU2237443622.USD","BK4568","LU0109394709.USD","BK1161","LU2417539215.USD","LU2237443549.SGD","PD","LU2462157665.USD","LU2476274308.USD","LU2476274720.SGD","LU2778985437.USD","IE00B3T34201.USD","LU2468319806.SGD","IE00B5MMRT66.SGD","LU0289739699.SGD","LU0029864427.USD","LU0432979614.USD","LU1169589451.USD","LU2488822045.USD","LU2089984988.USD","LU0889565916.HKD","LU0058720904.USD","LU1169590202.USD","LU1267930573.SGD","IE00BPRC5H50.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181201842","title":"异动解读｜阿斯利康盘中下跌3.05%，报184.205美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1181201842","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181201842?lang=zh_cn&edition=full","pubTime":"2026-07-01 22:40","pubTimestamp":1782916846,"startTime":"0","endTime":"0","summary":"7月1日，阿斯利康盘中下跌3.05%，报184.205美元/股，成交额1.52亿美元。阿斯利康所在的制药行业中，个股普遍承压，其中礼来跌1.43%，强生跌0.81%，默沙东跌1.90%，诺和诺德涨2.75%，辉瑞跌0.19%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646354848","title":"阿斯利康(AZN)与第一三共重磅新药获欧盟CHMP推荐批准 拟用于三阴性乳腺癌成年患者治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2646354848","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646354848?lang=zh_cn&edition=full","pubTime":"2026-06-26 19:17","pubTimestamp":1782472640,"startTime":"0","endTime":"0","summary":"金吾财讯 | 医药巨头阿斯利康 与日本第一三共联合开发的新一代抗癌药物 Datroway获欧洲药品管理局下属的人用药品委员会推荐批准作为单药一线疗法，用于治疗不适合接受 PD-1/PD-L1 抑制剂的不可切除或转移性三阴性乳腺癌成年患者。CHMP 的积极推荐主要基于 TROPION-Breast02 第三期全球临床试验的压倒性数据。业内分析认为，该管线的顺利推进将进一步夯实阿斯利康与第一三共在全球 ADC 药物赛道的霸主地位，并为两家公司未来的营收增长注入强劲的确定性。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250107/ZWE1ODViOTJlYWU0Yzg0YTU1MDJhZDdhZjY5ZjlmNDM0MDU5MzAwNzIw.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ZWE1ODViOTJlYWU0Yzg0YTU1MDJhZDdhZjY5ZjlmNDM0MDU5MzAwNzIw.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"301958","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZNH","LU2237443978.SGD","LU0310800379.SGD","LU0320765992.SGD","LU2236285917.USD","FESXmain","LU0128525929.USD","LU2237443382.USD","BK4087","LU1829250122.USD","BK4007","IE00B3T34201.USD","LU0289739699.SGD","LU2417539215.USD","LU2237443895.HKD","LU2237443549.SGD","BK4568","LU0109394709.USD","LU0029864427.USD","LU2462157665.USD","FSXEmain","LU2237443465.HKD","LU2237443622.USD","LU0058720904.USD","LU0432979614.USD","LU0708994859.HKD","LU1267930573.SGD","BK4588","LU0889565916.HKD","BK4585","CHMP","LU2456880835.USD","AZN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644435217","title":"辉瑞等制药巨头复制“英国剧本”：以撤资施压德国，倒逼欧洲放宽药价管控","url":"https://stock-news.laohu8.com/highlight/detail?id=2644435217","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644435217?lang=zh_cn&edition=full","pubTime":"2026-06-17 20:32","pubTimestamp":1781699555,"startTime":"0","endTime":"0","summary":"智通财经APP注意到，面对欧洲各国首都对药品定价的抵制，全球制药公司正在搬出近期在英国取得成功的“老剧本”：以撤回投资和扩张计划为威胁，向政策制定者施压。最新的目标是德国，该国目前正在辩论一项旨在收紧药品支出的立法。辉瑞上周致信德国总理，警告称由于该国目前的药品定价政策，其在德国的投资正面临风险；而阿斯利康则警告称，如果这些变革付诸实施，它可能不会在德国推出新药。","market":"hk","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455695.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ELIL","LU0353189680.USD","LU2237443622.USD","LU0820561909.HKD","IE00BWXC8680.SGD","SG9999001176.USD","LU0109391861.USD","LU0198837287.USD","LU0323591593.USD","LU0079474960.USD","ELIS","LU0128525929.USD","LU2111349929.HKD","LU2468319806.SGD","IE00BBT3K403.USD","LU0316494557.USD","LU2491050154.USD","LU0097036916.USD","BK4588","LU2756315664.SGD","LU0471298694.HKD","GB00BDT5M118.USD","IE0004445015.USD","IE00B4R5TH58.HKD","LU0640476718.USD","IE00BK4W5L77.USD","LU1868836914.USD","LU0029864427.USD","LU2596442595.SGD","IE00B2B36J28.USD","IE00BFSS7M15.SGD","LU1061106388.HKD","SG9999011175.SGD","LU2237443465.HKD","LU0058720904.USD","BK4007","IE00B4JS1V06.HKD","LU1988902786.USD","IE00BLSP4239.USD","LU0466842654.USD","LU2462157665.USD","LU2552382132.HKD","LU2112291526.USD","SG9999018865.SGD","LU0672654240.SGD","LU2237443895.HKD","IE00BKPKM429.USD","LU0289739699.SGD","LU0158827948.USD","LU1551013425.SGD","SGXZ51526630.SGD","LU2168564065.EUR","LU0210536198.USD","LU2552382215.SGD","IE00BJLML261.HKD","LU0094547139.USD","SG9999014898.SGD","LU2602419157.SGD","LU0256863902.USD","IE0009355771.USD","LU2461242641.AUD","LU2471134952.CNY","LU2023250330.USD","LU1804176565.USD","LU0320765059.SGD","LU1894683264.USD","IE000M9KFDE8.USD","LU2750360997.AUD","BK4534","IE00BJJMRY28.SGD","LU1035775433.USD","LU1894683348.USD","LU2023251221.USD","LU0109394709.USD","LU2471134796.USD","IE00BLSP4452.SGD","LU1232071149.USD","LU0321505439.SGD","SG9999015978.USD","LU2063271972.USD","LU2746668974.SGD","LU0266013472.USD","LU1883839398.USD","SG9999002232.USD","LU0353189763.USD","LU0823416689.USD","LU2265009873.SGD","LU0385154629.USD","LU0225283273.USD","LU2552382058.USD","LU0203201768.USD","LU2028103732.USD","SGXZ57979304.SGD","SG9999013999.USD","IE00BFTCPJ56.SGD","LU1989771016.USD","LU0238689110.USD","LU0823434583.USD","LU1023059063.AUD","LU1127390331.HKD","LU2491049909.HKD","LU2750360641.GBP","IE00B1XK9C88.USD","IE0004445239.USD","LLY","LU0889565916.HKD","LU1868837136.USD","LU1323610961.USD","IE0002270589.USD","LU1720051017.SGD","LU2168563687.JPY","LU0868494617.USD","LU2023250504.SGD","LU2324357040.USD","LU0006306889.USD","LU2896262040.SGD","LU1720051108.HKD","SG9999015986.USD","IE00BK4W5M84.HKD","PFE","SGXZ31699556.SGD","LU2237443549.SGD","LU0320765992.SGD","LU2106854487.HKD","LU1057294990.SGD","BK4550","BK4599","IE00B1BXHZ80.USD","LU2360106947.USD","LU0106261372.USD","BK4568","LU1868837300.USD","BK4585","LU0823434740.USD","LU2213496289.HKD","LU2236285917.USD","LU0708994859.HKD","LU1066053197.SGD","LU1291159041.SGD","LU0471298777.SGD","LU2491050071.SGD","LU2746668461.USD","LU0820561818.USD","IE0005OL40V9.USD","LU0225771236.USD","LU2237443978.SGD","LU2361044865.SGD","LU0256863811.USD","LU2264538146.SGD","LU0432979614.USD","LU1814569148.SGD","LU1917777945.USD","IE00BFSS8Q28.SGD","LLYX","LU0203202063.USD","LU0882574055.USD","LU1064131342.USD","IE00B19Z3B42.SGD","LU0061475181.USD","LU0787776722.HKD","LU2089283258.USD","LU1623119135.USD","LU2361045086.USD","SG9999014914.USD","LU0683600562.USD","LU2211815571.USD","LU0985481810.HKD","SG9999003800.SGD","SG9999017495.SGD","LU1066051498.USD","LU0096364046.USD","LU0133085943.USD","LU0158827781.USD","LU1093756168.USD","BK4592","LU0114720955.EUR","LU0820562030.AUD","LU0354030438.USD","SG9999001176.SGD","LU0708995401.HKD","LU0310800379.SGD","LU0306807586.USD","LU2168564222.USD","LU2471134523.USD","LU2471134879.HKD","IE0002141913.USD","LU2087625088.SGD","SG9999018857.SGD","LU2756315318.SGD","SG9999015945.SGD","IE00B3T34201.USD","LU2271345857.HKD","IE00B19Z3581.USD","IE00BN29S564.USD","LU1093756325.SGD","LU1983299246.USD","SG9999015952.SGD","LU0225284248.USD","LU1868836757.USD","LU2237438978.USD","LU2237443382.USD","LU1974910355.USD","LU2108987350.USD","LU2168564149.EUR","LU0354030511.USD","SG9999002224.SGD","LU1829250122.USD","LU0689472784.USD","LU2089984988.USD","LU0234572021.USD","LU0943347566.SGD","LU1145028129.USD","LU2361044949.HKD","LU1280957306.USD","LU1629891620.HKD","SGXZ99366536.SGD","IE0001KFT4U8.USD","LU1548497426.USD","LU2168564495.EUR","LU1267930573.SGD","LU1551013342.USD","LU0417517546.SGD","BK4533","LU0882574139.USD","LU0170899867.USD","LU1069344957.HKD","AZN","LU2357305700.SGD","IE00BJT1NW94.SGD","LU0786609619.USD","LLII","LU2089284900.SGD","BK4581","AZNH","IE00B775H168.HKD","LU0964807845.USD","IE00BJJMRZ35.SGD","LU1267930730.SGD","LU1868836591.USD","IE00B7KXQ091.USD","IE00BKDWB100.SGD","SG9999014880.SGD","IE00BJJMRX11.SGD","LU1712237335.SGD","SGXZ81514606.USD","LU0122379950.USD","LU0321505868.SGD","LLYZ","LU2417539215.USD","BK4516","LU2456880835.USD","LU0306806265.USD","LU1366192091.USD","SG9999014906.USD","LU0456855351.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642189402","title":"重返肿瘤核心战场 葛兰素史克(GSK.US)能否借Nuvalent缩小与阿斯利康差距？","url":"https://stock-news.laohu8.com/highlight/detail?id=2642189402","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642189402?lang=zh_cn&edition=full","pubTime":"2026-06-11 15:56","pubTimestamp":1781164594,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，葛兰素史克以创纪录的106亿美元收购美国生物技术公司Nuvalent，此举将加快这家英国制药巨头旗下抗癌药物业务的重建步伐，以应对来自更大竞争对手阿斯利康和罗氏的竞争压力。米尔斯在周二宣布收购Nuvalent后对记者表示。葛兰素史克并不打算在全部肿瘤领域与默沙东、阿斯利康或罗氏正面竞争，但将其视为潜在的增长领域。收购Nuvalent将为葛兰素史克产品组合增添两款晚期药物。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453096.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU2237443465.HKD","LU0320765992.SGD","LU2237443382.USD","BK4588","LU2237443622.USD","LU2462157665.USD","LU2417539215.USD","GSK.UK","LU2236285917.USD","LU0289739699.SGD","IE00B3T34201.USD","BK4532","LU2237443895.HKD","AZNH","LU0889565916.HKD","LU0109394709.USD","BK4007","BK4568","BK4539","LU0058720904.USD","LU2237443978.SGD","LU2456880835.USD","LU2237443549.SGD","NUVL","AZN","BK4585","BK4139","GSKH","LU1829250122.USD","GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159679098","title":"异动解读｜阿斯利康盘中下跌3.03%，口服减肥药数据竞争力逊于同业叠加管线压力","url":"https://stock-news.laohu8.com/highlight/detail?id=1159679098","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159679098?lang=zh_cn&edition=full","pubTime":"2026-06-11 01:34","pubTimestamp":1781112877,"startTime":"0","endTime":"0","summary":"6月10日，阿斯利康盘中下跌3.03%，报177.88美元/股，成交额1.96亿美元。消息面上，公司近日公布口服减肥药elecoglipron II期数据，最高剂量组36周减重11.8%，低于诺和诺德口服Wegovy约14%的减重幅度及礼来Foundayo约12%的水平，市场对其肥胖赛道竞争力存疑。此外，核心管线camizestrant此前遭FDA延长审评周期，管线不确定性持续累积。制药板块同业中，诺和诺德涨2.69%、强生涨0.81%，阿斯利康跌幅明显超出行业整体水平，反映市场对其管线兑现能力的担忧。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642452868","title":"阿斯利康加入减肥药赛道：口服药减重11.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2642452868","media":"华尔街见闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642452868?lang=zh_cn&edition=full","pubTime":"2026-06-09 14:19","pubTimestamp":1780985960,"startTime":"0","endTime":"0","summary":"阿斯利康的口服减肥药elecoglipron二期数据亮眼，36周内减重11.8%。虽效果略逊于礼来，但5%的副作用退出率远低于礼来的17%，且无需空腹。目前该药已进三期，正推进与心肾药联合开发以形成差异化竞争。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3774191","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZNH","LU0320765992.SGD","LU2237443895.HKD","AZN","LU2237443549.SGD","LU2237443465.HKD","BK4568","LU2237443622.USD","BK4588","LU0889565916.HKD","LU0109394709.USD","LU0058720904.USD","LU2236285917.USD","LU2237443382.USD","LU2417539215.USD","IE00B3T34201.USD","LU1829250122.USD","LU0289739699.SGD","LU2462157665.USD","LU2456880835.USD","BK4585","BK4007","LU2237443978.SGD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1163381786","title":"阿斯利康GLP-1口服药在糖尿病与肥胖症试验中通过早期考验","url":"https://stock-news.laohu8.com/highlight/detail?id=1163381786","media":"投资观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163381786?lang=zh_cn&edition=full","pubTime":"2026-06-09 06:27","pubTimestamp":1780957629,"startTime":"0","endTime":"0","summary":"根据周一在美国糖尿病协会年度会议上公布的二期试验结果，阿斯利康的实验性GLP-1口服药在为期36周的治疗中，使肥胖患者的体重平均降低了近12%。同时，该药物将糖尿病患者的糖化血红蛋白水平——一项衡量血糖的关键指标——平均降低了1.9个百分点。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4144","LU2237443465.HKD","LU2462157665.USD","LU0889565916.HKD","LU2237443978.SGD","LU2237443622.USD","AZNH","IE00B3T34201.USD","LU0289739699.SGD","LU0058720904.USD","BK4007","LU2236285917.USD","BK4568","LU2456880835.USD","LU0320765992.SGD","BK4590","GLP","LU2237443895.HKD","LU2417539215.USD","LU1829250122.USD","LU2237443382.USD","AZN","LU2237443549.SGD","LU0109394709.USD","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189391449","title":"异动解读｜阿斯利康盘中上涨3.06%，肝癌免疫联合疗法III期数据积极叠加制药板块整体走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1189391449","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189391449?lang=zh_cn&edition=full","pubTime":"2026-06-04 22:37","pubTimestamp":1780583874,"startTime":"0","endTime":"0","summary":"6月4日，阿斯利康盘中上涨3.06%，报181.765美元/股，成交额8129.96万美元。该积极数据有效对冲了此前anselamimab治疗轻链淀粉样变性III期临床未达主要终点的利空情绪。此外，制药板块当日整体走强，礼来涨4.63%、诺和诺德涨4.62%、默沙东涨3.66%、强生涨1.96%、辉瑞涨1.62%，板块联动效应助推公司股价反弹。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112961216","title":"异动解读｜阿斯利康盘前下跌3.18%，III期临床未达主要终点影响持续发酵","url":"https://stock-news.laohu8.com/highlight/detail?id=1112961216","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112961216?lang=zh_cn&edition=full","pubTime":"2026-06-03 18:35","pubTimestamp":1780482907,"startTime":"0","endTime":"0","summary":"6月3日，阿斯利康盘前下跌3.18%，报171.94美元/股，成交额57.72万美元。消息面上，公司旗下Alexion罕见病部门此前披露，评估anselamimab治疗轻链淀粉样变性的CARES III期临床项目在总体患者人群中未达到主要终点。尽管预设Kappa亚组显示全因死亡率改善62%、心血管住院率降低71%，但整体数据未能达标，构成管线层面利空。当前制药板块同业表现相对平稳，礼来涨0.1%、强生涨0.11%、默沙东涨0.2%，阿斯利康跌幅明显超出行业整体水平，反映市场对其管线风险的持续定价。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZN"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.astrazeneca.com","stockEarnings":[{"period":"1week","weight":-0.0041},{"period":"1month","weight":0.0226},{"period":"3month","weight":-0.053},{"period":"6month","weight":-0.0008},{"period":"1year","weight":0.369},{"period":"ytd","weight":0.0343}],"compareEarnings":[{"period":"1week","weight":0.0139},{"period":"1month","weight":0.0186},{"period":"3month","weight":0.1396},{"period":"6month","weight":0.0895},{"period":"1year","weight":0.2014},{"period":"ytd","weight":0.1017}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"阿斯利康股份有限公司于1992年6月17日根据1985年《公司法》在英格兰和威尔士注册成立。该公司是在1993年将Imperial化学工业公司的制药、农化和特种化学品业务分拆时成立的。1999年，公司出售了特种化学品业务。同样在1999年，该公司与瑞典Astra公司合并。2000年，该公司将农化业务分拆，并将其与诺华公司的同类业务合并，成立了一家新的公司Syngenta AG。2007年，集团收购了位于美国的生物制剂和疫苗企业MedImmune。2021年，集团收购了位于美国的罕见病企业Alexion。","yearOnYearQuotes":[{"month":1,"riseRate":0.515152,"avgChangeRate":0.001662},{"month":2,"riseRate":0.424242,"avgChangeRate":-0.012868},{"month":3,"riseRate":0.545455,"avgChangeRate":0.025511},{"month":4,"riseRate":0.636364,"avgChangeRate":0.028791},{"month":5,"riseRate":0.515152,"avgChangeRate":0.008212},{"month":6,"riseRate":0.470588,"avgChangeRate":0.018421},{"month":7,"riseRate":0.617647,"avgChangeRate":-0.002355},{"month":8,"riseRate":0.484848,"avgChangeRate":0.004788},{"month":9,"riseRate":0.545455,"avgChangeRate":0.001232},{"month":10,"riseRate":0.545455,"avgChangeRate":0.015301},{"month":11,"riseRate":0.515152,"avgChangeRate":0.003764},{"month":12,"riseRate":0.545455,"avgChangeRate":0.007464}],"exchange":"NYSE","name":"阿斯利康","nameEN":"AstraZeneca PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供阿斯利康(AZN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"阿斯利康,AZN,阿斯利康股票,阿斯利康股票老虎,阿斯利康股票老虎国际,阿斯利康行情,阿斯利康股票行情,阿斯利康股价,阿斯利康股市,阿斯利康股票价格,阿斯利康股票交易,阿斯利康股票购买,阿斯利康股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供阿斯利康(AZN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}